KALAMAZOO, Mich. - NanoVir of Kalamazoo was recently awarded approximately $1 million from the National Institutes of Health (NIH) to further its research on the treatment of human papillomavirus (HPV).

James Bashkin and Chris Fisher, two scientists from both the University of Missouri, St. Louis, and NanoVir, a Kalamazoo, Mich.-based biotechnology company, have been honored with the Tibbetts Award in recognition of their work in identifying a potential treatment to fight the virus that causes cervical cancer.

Click here for the full article. The article is available to subscribers of C&E News or for purchase.

KALAMAZOO, Mich. and ST. LOUIS, Mo: NanoVir, Inc. has received an "Advanced Technology" small business grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), the company announced today. The award for approximately $600,000 over two years will support efforts to create drugs to treat human papillomavirus (HPV). Typical NIH small business grants are for less than $100,000.

Washington, D.C.: James K. Bashkin, Ph.D. of NanoVir, LLC in St. Louis, Missouri has been selected as one of the winners of the 2006 Tibbetts Awards. Dr. Bashkin and his co-founder, Dr. Chris Fisher of Kalamazoo, MI will receive the award on Sept. 26 at the Wyndham Washington, located at 1400 M Street NW in Washington, D.C. NanoVir is located in St. Louis on the Campus of the University of Missouri-St. Louis.

Scientists from the University of Missouri-St. Louis and NanoVir announced today the identification of a potential new treatment to fight the virus that causes cervical cancer, the second leading killer of women by cancer worldwide.